ATE437889T1 - Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration - Google Patents
Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegenerationInfo
- Publication number
- ATE437889T1 ATE437889T1 AT05026397T AT05026397T ATE437889T1 AT E437889 T1 ATE437889 T1 AT E437889T1 AT 05026397 T AT05026397 T AT 05026397T AT 05026397 T AT05026397 T AT 05026397T AT E437889 T1 ATE437889 T1 AT E437889T1
- Authority
- AT
- Austria
- Prior art keywords
- gpi
- cells
- tissue regeneration
- tumour
- chemokine
- Prior art date
Links
- 230000017423 tissue regeneration Effects 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000019034 Chemokines Human genes 0.000 abstract 3
- 108010012236 Chemokines Proteins 0.000 abstract 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 abstract 3
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- 230000003966 vascular damage Effects 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000004873 anchoring Methods 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05026397A EP1792914B1 (de) | 2005-12-02 | 2005-12-02 | Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437889T1 true ATE437889T1 (de) | 2009-08-15 |
Family
ID=36047948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05026397T ATE437889T1 (de) | 2005-12-02 | 2005-12-02 | Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120208769A1 (de) |
| EP (1) | EP1792914B1 (de) |
| AT (1) | ATE437889T1 (de) |
| AU (1) | AU2006319440B2 (de) |
| CA (1) | CA2631587C (de) |
| DE (1) | DE602005015733D1 (de) |
| WO (1) | WO2007062844A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009014382A2 (en) * | 2007-07-23 | 2009-01-29 | Postech Academy-Industry Foundation | Cxcl11 adjuvant compositions and uses thereof |
| CN102221608A (zh) * | 2011-04-06 | 2011-10-19 | 浙江大学医学院附属第一医院 | 一种抗体组合物及其应用 |
| US9156897B2 (en) * | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| EP3218477A4 (de) * | 2014-11-10 | 2018-07-18 | The Board of Trustees of The Leland Stanford Junior University | Zusammensetzungen und verfahren zur expression von polypeptiden auf der oberfläche von zellen |
| JP6786526B2 (ja) | 2015-06-03 | 2020-11-18 | ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． | 改変されたｃｃｌ２０ロックド二量体ポリペプチド |
| US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
| WO2020146857A1 (en) * | 2019-01-11 | 2020-07-16 | Arbele Limited | Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof |
| CN114651002B (zh) * | 2019-11-07 | 2024-12-13 | 武汉华大吉诺因生物科技有限公司 | 肿瘤特异性多肽序列及其应用 |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022204267A1 (en) | 2021-03-24 | 2022-09-29 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2903999A (en) * | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| WO2003017944A2 (en) * | 2001-08-27 | 2003-03-06 | Greenville Hospital System | Gpi-anchored cytokines |
| AU2006304387A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
-
2005
- 2005-12-02 AT AT05026397T patent/ATE437889T1/de not_active IP Right Cessation
- 2005-12-02 DE DE602005015733T patent/DE602005015733D1/de not_active Expired - Lifetime
- 2005-12-02 EP EP05026397A patent/EP1792914B1/de not_active Expired - Lifetime
-
2006
- 2006-11-30 US US12/085,882 patent/US20120208769A1/en not_active Abandoned
- 2006-11-30 WO PCT/EP2006/011508 patent/WO2007062844A1/en not_active Ceased
- 2006-11-30 AU AU2006319440A patent/AU2006319440B2/en not_active Ceased
- 2006-11-30 CA CA2631587A patent/CA2631587C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120208769A1 (en) | 2012-08-16 |
| AU2006319440B2 (en) | 2012-02-09 |
| EP1792914A1 (de) | 2007-06-06 |
| CA2631587C (en) | 2013-01-15 |
| EP1792914B1 (de) | 2009-07-29 |
| DE602005015733D1 (de) | 2009-09-10 |
| AU2006319440A1 (en) | 2007-06-07 |
| WO2007062844A1 (en) | 2007-06-07 |
| CA2631587A1 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005015733D1 (de) | Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration | |
| US11730761B2 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| JP2023175799A (ja) | がんの免疫療法のためのｎｋｇ２ｄ－ｉｇ融合タンパク質 | |
| ES2438965T3 (es) | Composiciones y métodos para administrar células madre | |
| KR20200046065A (ko) | 암을 치료하기 위한 병용 면역 요법 및 사이토카인 조절 요법 | |
| WO2006047603A3 (en) | Ungulates with genetically modified immune systems | |
| BR112018067379A2 (pt) | conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição. | |
| CL2011003333A1 (es) | El compuesto n-{1s-[2r-(6,6'-difluoro-3'-{4s-hidroxi-1-[2s-(2s-metilamino-propionilamino)-butiril]-pirrolidin-2r-ilmetil}-1h,1'h-[2,2']biindolil-3-ilmetil)-4s-hidroxi-pirrolidin-1-carbonil]-propil}-2s-metilamino-propionamida; composicion farmaceutica; procedimiento de preparacion; compuestos intermediarios; utiles en el tratamiento de un trastorno proliferativo, tal como cancer, entre otros. | |
| HRP20240362T1 (hr) | Pripravci i postupci namijenjeni liječenju hematološkog raka, koji ciljaju na međudjelovanje između sirp-alfa i cd47 | |
| CY1117115T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου | |
| CY1115774T1 (el) | Υπερδιακλαδισμενα πολυανθρακικα για την διαλυτοποιηση δυσδιαλυτων δραστικων ουσιων | |
| BRPI0513534A (pt) | inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso | |
| BR112018007982A2 (pt) | composição, reação enzimática e método para preparar um copolímero de enxerto | |
| PE20110435A1 (es) | Composiciones antagonistas del pd-1 | |
| AR073829A1 (es) | Variantes de inmunoglobulinas y sus usos. | |
| SG10201805411YA (en) | Chimeric antigen receptors | |
| UY33034A (es) | Materiales y métodos para el tratamiento o prevención de enfermedades asociadas al her-3 | |
| Zhao et al. | The tumour vasculature as a target to modulate leucocyte trafficking | |
| PE20211266A1 (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas | |
| Levesque et al. | Cell adhesion molecules in normal and malignant hematopoiesis: from bench to bedside | |
| KR20200014418A (ko) | 암 요법을 위한 치료학적 세포자살성 세포 | |
| Weisdorf | The role of second transplants for leukemia | |
| PE20200602A1 (es) | Compuesto macrociclico y sus usos | |
| ATE376824T1 (de) | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln | |
| CO2025013357A2 (es) | Conjugados de ligando-fármaco citotóxico y usos farmacéuticos de estos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |